A Phase 2 interventional study of Bicalutamide and Anastrozole in Puberty, Precocious, sponsored by AstraZeneca. Completed at 15 sites in 6 countries. Open to male participants aged 2 Years to 13 Years. Per ClinicalTrials.gov, last updated 2018-06-26.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Puberty, Precocious with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Puberty, Precocious · United States.
Among the 21 studies in Puberty, Precocious with a site in United States, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2004, is one of 5 in phase 2, and was the 5th registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →4 of the 21 studies in Puberty, Precocious with a site in United States are open now. Recruiting first, the newest first:
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 6 wk–120 yrs
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 1 days–99 yrs
Atossa Therapeutics, Inc. · Sites in United States
Ages 4–9 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 13 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1982; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 55 across the 15 interventional studies, 850 across the 5 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 21 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Puberty, Precocious with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty in boys including growth in height, and development of muscles and sexual organs .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(Note: Ketoconazole and Spironolactone are considered acceptable as is prior use of anastrozole or other aromatase inhibitors)
(Note: for subjects who received such previous treatment only a single assessment is needed if it was taken immediately prior to beginning treatment and > 6 months prior to study entry)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bicalutamide in combination with Anastrozole
Drug: Bicalutamide · Drug: Anastrozole
oral
Also known as: Casodex
oral
Also known as: Arimidex, ZD1033
Change in Growth Rate (cm/Year)
Change in growth rate after 12 months relative to the growth rate during the ≥6 month pre-study period, based on raw height data (cm/year).
Time frame: Assessed after 12 months treatment
Change in Growth Rate (SD Units)
Change in growth rate after 12 months relative to the growth rate during the ≥6 month pre-study period, calculated after adjustment for the chronological age of the patient (expressed as a standard deviation \[SD\] score).
Time frame: Assessed after 12 months treatment
Change in Growth Rate (cm/Year)
Change in growth rate after 6 months of treatment relative to the growth rate during the ≥6 months pre-study period.
Time frame: Assessed after 6 months treatment
Change in Growth Rate (SD Units)
Change in growth rate after 6 months of treatment relative to the growth rate during the ≥6 months pre-study period.
Time frame: Assessed after 6 months treatment
Change in Bone Age Maturation Rate (cm/Year)
Radiographs were used to assess the bone age at ≥6 months pre-study, baseline, 6 and 12 months. The rate of change in bone age at baseline was calculated from a radiograph taken at least 6 months prior to study enrolment. The change in bone maturation after 6 months of treatment was calculated relative to the rate of change in bone age during the ≥ 6 months pre-study period.
Time frame: Assessed after 6 and 12 months treatment
Change in Bone Age to Chronological Age Ratio
Change in bone age to chronological age ratio after 6 and 12 months treatment relative to the baseline ratio for all patients.
Time frame: Assessed after 6 and 12 months of treatment
Number of Patients With Height Between 5th and 95th Percentile
The number of patients whose height lies between the 5th and 95th percentiles (using the percentile tables on the WHO database) for chronological age at the 12 month assessment.
Time frame: Assessed after 3, 6, 9 and 12 months of treatment
Change in Predicted Adult Height (PAH)
Radiographs are used to assess the bone age, the change in predicted adult height (PAH) is calculated from the bone age using the Bayley and Pinneau Method. The change in PAH is be calculated by subtracting the PAH at baseline from the PAH at 12 months.
Time frame: Assessed after 12 months treatment
Change in Average Testicular Volume
Testicular volume of both testes was measured using either ultrasound or an orchidometer. Testicular volume was measured at baseline and at 6 and 12 months. The change in testicular volume from baseline was calculated for the left and right testicle as well as the average across both testes by subtracting the baseline volume from the volumes at 6 and 12 months within each patient.
Time frame: Assessed after 6 and 12 months of treatment
The first patient was enrolled on 22 November 2004 and the last patient completed the 12 months visit on 7 May 2008. Patients were allocated treatment at 9 centres in 3 countries: India, the UK and the USA. Care for two patients, transferred from one US to a new approved US centre, therefore, patients were treated at 10 centres in total
| Milestone | Open Label Bicalutamide With Anastrozole |
|---|---|
| Started | 14 |
| Completed | 13 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
Change in growth rate after 12 months relative to the growth rate during the ≥6 month pre-study period, based on raw height data (cm/year).
| cm/year | Open Label Bicalutamide With Anastrozole |
|---|---|
| Change in Growth Rate (cm/Year) | -1.62 ± 5.13 |
Change in growth rate after 12 months relative to the growth rate during the ≥6 month pre-study period, calculated after adjustment for the chronological age of the patient (expressed as a standard deviation \[SD\] score).
| SD units | Open Label Bicalutamide With Anastrozole |
|---|---|
| Change in Growth Rate (SD Units) | -0.07 ± 1.78 |
Change in growth rate after 6 months of treatment relative to the growth rate during the ≥6 months pre-study period.
| cm/year | Open Label Bicalutamide With Anastrozole |
|---|---|
| Change in Growth Rate (cm/Year) | -0.70 ± 5.77 |
Change in growth rate after 6 months of treatment relative to the growth rate during the ≥6 months pre-study period.
| SD units | Open Label Bicalutamide With Anastrozole |
|---|---|
| Change in Growth Rate (SD Units) | -0.14 ± 1.67 |
Radiographs were used to assess the bone age at ≥6 months pre-study, baseline, 6 and 12 months. The rate of change in bone age at baseline was calculated from a radiograph taken at least 6 months prior to study enrolment. The change in bone maturation after 6 months of treatment was calculated relative to the rate of change in bone age during the ≥ 6 months pre-study period.
| cm/year | Open Label Bicalutamide With Anastrozole |
|---|---|
| After 6 months treatment | -2.03 ± 0.38 |
| After 12 months treatment | -2.29 ± 0.51 |
Change in bone age to chronological age ratio after 6 and 12 months treatment relative to the baseline ratio for all patients.
| Ratio | Open Label Bicalutamide With Anastrozole |
|---|---|
| After 6 months treatment | -0.09 ± 0.14 |
| After 12 months treatment | -0.24 ± 0.18 |
The number of patients whose height lies between the 5th and 95th percentiles (using the percentile tables on the WHO database) for chronological age at the 12 month assessment.
| Participants | Open Label Bicalutamide With Anastrozole |
|---|---|
| After 3 months treatment | 3 |
| After 6 months treatment | 3 |
| After 9 months treatment | 3 |
| After 12 months treatment | 3 |
Radiographs are used to assess the bone age, the change in predicted adult height (PAH) is calculated from the bone age using the Bayley and Pinneau Method. The change in PAH is be calculated by subtracting the PAH at baseline from the PAH at 12 months.
| cm | Open Label Bicalutamide With Anastrozole |
|---|---|
| Change in Predicted Adult Height (PAH) | 6.21 ± 3.93 |
Testicular volume of both testes was measured using either ultrasound or an orchidometer. Testicular volume was measured at baseline and at 6 and 12 months. The change in testicular volume from baseline was calculated for the left and right testicle as well as the average across both testes by subtracting the baseline volume from the volumes at 6 and 12 months within each patient.
| mL | Open Label Bicalutamide With Anastrozole |
|---|---|
| After 6 months treatment | 1.46 ± 2.29 |
| After 12 months treatment | 2.69 ± 2.51 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label Bicalutamide With Anastrozole | 0/14 (0%) | 0/14 (0%) | 13/14 (92.9%) |
| Event | Open Label Bicalutamide With Anastrozole |
|---|---|
| GynaecomastiaReproductive system and breast disorders | 7/14 |
| Precocious PubertyEndocrine disorders | 6/14 |
| VomitingGastrointestinal disorders | 5/14 |
| HeadacheNervous system disorders | 3/14 |
| PyrexiaGeneral disorders | 3/14 |
| Abdominal PainGastrointestinal disorders | 2/14 |
| AcneSkin and subcutaneous tissue disorders | 2/14 |
| Breast TendernessReproductive system and breast disorders | 2/14 |
| ConjunctivitisEye disorders | 2/14 |
| Croup InfectiousInfections and infestations | 2/14 |
| Age, Continuous(Years) | Open Label Bicalutamide With Anastrozole |
|---|---|
| Median | 3.5 (2 to 9) |
| Sex: Female, Male(Participants) | Open Label Bicalutamide With Anastrozole |
|---|---|
| Female | 0 |
| Male | 14 |
| Race/Ethnicity, Customized(Participants) | Open Label Bicalutamide With Anastrozole |
|---|---|
| Race — Caucasian | 12 |
| Race — Black | 1 |
| Race — Other | 1 |
| Race/Ethnicity, Customized(Participants) | Open Label Bicalutamide With Anastrozole |
|---|---|
| Ethnic group — Hispanic/Latino | 1 |
| Ethnic group — African/American | 1 |
| Ethnic group — Asian | 3 |
| Ethnic group — Not Applicable | 9 |
Ran from Nov 2004 to primary completion in May 2008, 42 months.
Results were first posted in Jul 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bicalutamide · Anastrozole